Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05884788
Other study ID # ET22000324
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2023
Est. completion date March 2024

Study information

Verified date September 2023
Source Centre Leon Berard
Contact Clarisse VINDRY, Resident
Phone 0478782657
Email clarisse.vindry@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study wishes to focus on the life course of patients, beyond the moments of suffering experienced at the time of the request for euthanasia. It is based on the perspective that the patient's account of his or her life course can be a source of information for better understanding and accompanying patients requesting euthanasia.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major patients - With cancer in the palliative phase, i.e. with an incurable disease according to current knowledge. - Expressing a request for euthanasia in terms evoking a request for death with the intervention of an outside person. - Non-opposition to the study after full written information. Exclusion Criteria: - Severe decompensated psychiatric pathology - Vulnerable persons defined here as pregnant women, parturients and persons under legal protection or unable to express their consent - Inability to conduct an interview

Study Design


Related Conditions & MeSH terms


Intervention

Other:
free interview, and questionnaires in a second time
After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible. Each interview will be conducted by the same person to allow for better interpersonal reproducibility. After the interview, the patients will be seen again to complete two questionnaires: An attachment questionnaire: Relationship Scales Questionnaire A questionnaire on symptoms: Distress thermometer

Locations

Country Name City State
France Centre Léon Bérard Lyon

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Description of the life stories of patients requesting euthanasia to explore which life experiences are brought forward when making this request, in a context of advanced oncological pathology. The main objective is to describe the life stories of patients requesting euthanasia in order to discover which life experiences are reasoning in the formulation of this request, in a context of advanced oncological pathology.
The investigators carry out a descriptive analysis of the interviews. The interviews will be analyzed as they are conducted, in order to identify themes of interest. The themes will be compared between the different interviews in order to identify possible trends.
One month
Secondary Calculation of the Bartholomew score Use of specific questionnaire (Relationship Scales Questionnaire of Batholomew) to describe the profiles of the patients in the study One month
Secondary Calculation of the distress thermometer's score Use of specific questionnaire (NCCN distress thermometer) to describe the profiles of the patients in the study One month
See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01583777 - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Phase 1